title: [Monotherapy with vigabatrin in the treatment of West's syndrome].
abstract: BACKGROUND
  Vigabatrin (VGB) was specifically synthesized to enhance inhibitory GABAergic transmission by elevating GABA levels via irreversible inhibition of GABA transaminase.
  
  
  METHODS
  This study was conducted to determine the efficacy of VGB introduced as monotherapy in 26 children fulfilled the criteria for diagnosis of West syndrome. Duration of follow-up was 24 months.
  
  
  RESULTS
  Following the introduction of VGB, 13 patients became seizure free, a special efficacy in one case of tuberous sclerosis. Relapses of infantile spasms occurred in 8 infants, generalized seizures developed in 4 infants, and partial seizures in 3, of whom 2 were eventually rendered seizure-free by increasing the dose. EEG features and age affecting the response rate. VGB has been well tolerated in children with agitation being the most commonly reported side effects, and one case required discontinuation of therapy.
  
  
  CONCLUSIONS
  VGB seems to be an effective an safe antiepileptic drug as primary monotherapy for West syndrome.
authors.affiliation: Servicio de Neuropediatría, Hospital Infantil Universitario Virgen del Rocío, Sevilla, España.
authors.forename: M
authors.initials: M
authors.lastname: Rufo
authors.forename: C
authors.initials: C
authors.lastname: Santiago
authors.forename: E
authors.initials: E
authors.lastname: Castro
authors.forename: O
authors.initials: O
authors.lastname: Ocaña
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011596:Psychomotor Disorders; D013036:Spasms, Infantile / Q000188:drug therapy*; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D000324:Adrenocorticotropic Hormone; D020888:Vigabatrin